“John’s experience in the areas of marketing, regulatory, reimbursement and financial accounting will be a significant benefit to Colorado Therapeutics as we prepare to launch our first FDA-cleared commercial product, XI‑S+,” said Joseph B. Horn, Colorado Therapeutics’ president and CEO. “His experience with surgical biologics products is particularly applicable to our product line, which has shown utility in the repair of hernia and other soft tissue applications. We welcome John to our team and look forward to capitalizing on his experience with our impending product launch as well as our open Series A financing.”
“From my experience, I believe that the team at Colorado Therapeutics has developed a truly unique biologic tissue product. The characteristics of XI-S+ will provide surgeons with a blend of strength, flexibility, and biocompatibility that is not currently available on the market in either synthetic or biologic products,” Lorbiecki added. “I’ve spent my career at a large, established medical device company. The opportunity to join a nimble, innovative organization at this stage of commercial growth was one I could not pass by.”
During his 25-year career at Medtronic, Lorbiecki held several positions of increasing responsibility, most recently as senior finance director of Strategic Scientific Operations, where he was responsible for developing long-term and annual operating goals, providing business support to clinical, regulatory, reimbursement, and other strategic scientific operations in the company. Prior to that role, Lorbiecki held two divisional chief financial officer roles, managed financial integration of multiple acquisitions, and provided analytical and strategic insight on high-value business development opportunities. During his term, he dedicated six years to managing the development of pricing strategy and tactics for the Cardiac Surgery division, including national accounts. He earned a M.B.A. from the University of Chicago and a bachelor of arts degree in economics from the University of St. Thomas in St. Paul, Minn.
Colorado Therapeutics is a commercial-stage company developing strong, durable and biocompatible tissue from xenogenic sources using a proprietary cross-linked tissue processing technology. Resulting tissue products demonstrate superior benefits compared to currently available biologic or synthetic products. XI-S+, Colorado Therapeutics first commercial product, received U.S. Food and Drug Administration 510(k) clearance in 2016 for implantation to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue membranes. Colorado Therapeutics’ products target the $2.25 billion U.S. soft tissue reinforcement and regeneration markets, and may have utility in a broad range of applications. Colorado Therapeutics’ corporate headquarters and pre-commercialization facilities are located in Broomfield, Colo.